▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Seth Robey

PharmTeam

Lab scientist by day. Motley Fool Contributor by night. Fusing a love for science and money into new biotech investment ideas. Follow @SethRobey on twitter.

Recent Articles by Seth Robey

Oct 24, 2014 by Seth Robey

3 Reasons Thermo Fisher Scientific Inc.'s Stock Could Tumble

Can Thermo Fisher Scientific execute on its massive growth opportunity, or will the doldrums of slow organic growth hold back its stock?

Oct 23, 2014 by Seth Robey

Eli Lilly & Co. Earnings: Patent Pains Continue

Eli Lilly has experienced one of the toughest patent loss challenges in the industry. Did they finally reach the bottom this quarter?

Oct 23, 2014 by Seth Robey

3 Reasons Thermo Fisher Scientific Inc.'s Stock Could Rise

Thermo Fisher Scientific's future rests on three pillars of growth, and a big-name acquisition may tip the scales in their favor.

Oct 22, 2014 by Seth Robey

Thermo Fisher Scientific Inc.'s Earnings: Buying Its Way to the Top

The laboratory equipment juggernaut showed explosive growth, but the market wasn't so impressed. Does Wall Street have this one backwards?

Oct 21, 2014 by Seth Robey

Is It Time to Buy Eli Lilly & Co.'s Stock?

Eli Lilly & Co. is promising big things, but has optimism in the stock gotten ahead of reality? It's time to ask if now's the right time to invest.

Oct 21, 2014 by Seth Robey

5 Things Thermo Fisher Scientific Inc.'s Management Wants You to Know

Thermo Fisher Scientific is in a strong position to exploit a growing genomics market. Management knows it -- and they really want you to know it, too.

Sep 22, 2014 by Seth Robey

3 Reasons Eli Lilly & Co.'s Stock Could Fall

Management at Eli Lilly & Co. has faced a mountain of challenges in the wake of debilitating patent losses, but the stock has held strong regardless. Here are three reasons that rally may not continue into the future.

Sep 2, 2014 by Seth Robey

3 Reasons Eli Lilly & Co.'s Stock Could Rise

With earnings tumbling over the patent cliff, can diabetes and oncology transform Eli Lilly into a Big Pharma turnaround story?

Aug 20, 2014 by Seth Robey

5 Things Eli Lilly and Co's Management Wants You to Know

At a critical time for the company, Eli Lilly's management has laid out its plans to return to growth and gave us a good look at what the future holds.

Aug 16, 2014 by Seth Robey

3 Building Blocks of a Wearable Technology Revolution

The sky is the limit for wearable medical technology, but it won't be as simple as slapping a smart watch on your wrist.

Jul 19, 2014 by Seth Robey

10 Problems Electronic Health Records Can Help Solve

Electronic health records will be a central player in the future of health care and health care reform, and they may be even more useful than you might think.

Jul 10, 2014 by Seth Robey

Are Cancer Vaccines Worth an Investment?

Immuno-oncology has been the darling of biotech investors, but growth in one segment of the industry might not look as strong as you think.

Jun 30, 2014 by Seth Robey

Why Are Companion Diagnostics So Important?

Patients, doctors, and investors have been excited about new frontiers in oncology, but can these drugs be useful without companion diagnostics?

Jun 15, 2014 by Seth Robey

Is Apple Disrupting Health Care's Disruptors?

With its new operating system and health app interface, Apple will enable doctors to play more of a role in patient-focused care. How will that change the landscape of health care IT providers?

Jun 2, 2014 by Seth Robey

ASCO 2014: Doubling Down on Next-Gen Cancer Drugs

What's better than a cancer treatment that binds specifically to its target? A therapy that specifically binds to two targets, of course.

Jun 2, 2014 by Seth Robey

ASCO Showdown: AstraZeneca vs. Clovis Oncology

The annual meeting brings together some of the world's most exciting emerging cancer treatments, and after only a day AztraZenica and Clovis are making waves as the compete in the lung cancer market.

May 28, 2014 by Seth Robey

3 Biotechs Worthy of a Stanley Cup

If these three drug makers were hockey teams, you can bet they'd have what it takes to compete at hockey's highest level.

Apr 25, 2014 by Seth Robey

3 Questions About a Big Pharma Megamerger

From pipelines to competitive landscapes, here are three questions that could shape a huge acquisition and the markets they operate in.

Mar 20, 2014 by Seth Robey

A Major Confidence Boost for this Health Care IT Provider

Veeva Systems overcame two major hurdles in the most recent quarter. Is it time for smooth sailing?

Mar 14, 2014 by Seth Robey

The NIH is Investing in an Alzheimer's Cure; Should You?

Can any of the number of companies struggling to cure Alzheimer's disease provide reliable investments?

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services